Mutational testing for NPM1, CEBPA, and FLT3 is advised in the 2010 European LeukemiaNet (ELN) recommendations for AML [1], and the 2017 update to the ELN recommendations lists three additional genes—RUNX1, ASXL1, and TP53—that can inform risk stratification, mainly based on experience with intensive chemotherapy (IC) in relatively younger patients [4]. This evidence concerns the gene NPM1 and acute myeloid leukemia.